# IB-Stim

Type: Product

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/ib-stim
Canonical HTML page: https://gethealthbrief.com/entity/ib-stim

## Recent coverage (1 stories)

### Relmada and NeurAxis Q4 Results Signal Pivotal 2026 for CNS Innovation
2026-03-20 14:51:25 · Sentiment: Neutral · Impact: 5/10 · Sources: 3

Relmada Therapeutics and NeurAxis reported Q4 2025 results, highlighting a strategic shift toward late-stage clinical readouts and expanded commercial coverage for CNS therapies. Both companies are positioning themselves as leaders in non-traditional treatments for depression and pediatric pain, respectively.
Full story: https://gethealthbrief.com/story/relmada-neuraxis-q4-2025-earnings-cns-trends

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.